Efficacy of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma: a controlled randomized trial

Transcatheter arterial chemoembolization (TACE) is an important therapy for hepatocellular carcinoma (HCC), but the recurrence rate is still high and the long-term survival is unsatisfactory. This study was to evaluate the efficacy of TACE combined thalidomide on HCC. From Aug. 2004 to Aug. 2006, 10...

Full description

Saved in:
Bibliographic Details
Published inAi zheng = Aizheng = Chinese journal of cancer Vol. 26; no. 8; p. 861
Main Authors Hao, Ming-Zhi, Lin, Hai-Lan, Chen, Qiang, Wu, Hui, Yu, Wen-Chang, Chen, Tang-Geng
Format Journal Article
LanguageChinese
Published China 01.08.2007
Subjects
Administration, Oral
Adult
Aged
Angiogenesis Inhibitors - adverse effects
Angiogenesis Inhibitors - therapeutic use
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - therapy
Chemoembolization, Therapeutic
Combined Modality Therapy
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Exanthema - chemically induced
Female
Floxuridine - administration & dosage
Follow-Up Studies
Humans
Liver Neoplasms - pathology
Liver Neoplasms - therapy
Male
Middle Aged
Neoplasm Staging
Organoplatinum Compounds - administration & dosage
Survival Rate
Thalidomide - adverse effects
Thalidomide - therapeutic use
Young Adult
Online AccessGet more information

Cover

More Information
Summary:Transcatheter arterial chemoembolization (TACE) is an important therapy for hepatocellular carcinoma (HCC), but the recurrence rate is still high and the long-term survival is unsatisfactory. This study was to evaluate the efficacy of TACE combined thalidomide on HCC. From Aug. 2004 to Aug. 2006, 108 patients with unresectable primary HCC were randomized into combination (TACE plus thalidomide) group and TACE group. Combination group received oral administration of thalidomide (200 mg/d) for 1-6 months. Both groups were treated with 0.4-1.6 g gemcitabine, 100-200 mg oxaliplatin, and 0.5-1.0 g floxuridine as chemotherapeutic drugs, ethanol, glutin, and iodolipol as ambolic agent in TACE. The side effects of thalidomide and survival of the patients were observed. The median survival period was 18 months [95% confidence interval (CI), 12-24 months] in combination group and 13 months (95% CI, 10-16 months) in TACE group. The 6-month, 1-year, and 2-year survival rates were 92.9%, 82.7%, and 58.4% respectively in c